Solventum (NYSE:SOLV) Price Target Raised to $105.00

Posted by Geri Gentry on Aug 9th, 2026

Solventum (NYSE:SOLV – Free Report) had its target price hoisted by Piper Sandler from $92.00 to $105.00 in a report issued on Thursday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other brokerages have also recently weighed in on SOLV. BMO Capital Markets assumed coverage on Solventum in a research report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price target on the stock. BTIG Research raised their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. UBS Group boosted their price objective on shares of Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Wedbush upped their target price on shares of Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $91.64.

View Our Latest Analysis on Solventum

Solventum Stock Performance

NYSE:SOLV opened at $83.00 on Thursday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.75 and a current ratio of 1.02. Solventum has a 52-week low of $62.38 and a 52-week high of $90.00. The firm has a market cap of $14.13 billion, a price-to-earnings ratio of 10.15, a PEG ratio of 1.18 and a beta of 0.60. The business’s fifty day moving average is $79.40 and its 200 day moving average is $74.44.

Solventum (NYSE:SOLV – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. During the same quarter in the prior year, the firm posted $1.69 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Research analysts predict that Solventum will post 7.25 EPS for the current year.

Institutional Trading of Solventum

Several institutional investors and hedge funds have recently modified their holdings of SOLV. United Services Automobile Association bought a new stake in shares of Solventum during the 1st quarter valued at about $239,000. Woodline Partners LP grew its holdings in shares of Solventum by 40.7% during the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after purchasing an additional 3,377 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after purchasing an additional 10,425 shares during the last quarter. First Trust Advisors LP increased its position in shares of Solventum by 5.8% in the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock worth $19,546,000 after purchasing an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Solventum in the second quarter worth approximately $766,000.

Key Headlines Impacting Solventum

Here are the key news stories impacting Solventum this week:

Positive Sentiment: Q2 results exceeded expectations. Solventum reported adjusted earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue of $2.21 billion also topped forecasts. Organic sales increased 9.5%, and revenue grew 2.2% year over year. Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
Positive Sentiment: Management raised 2026 earnings guidance to $7.10-$7.20 per share, above its previous outlook. Strong cash flow and the company’s share-repurchase activity further support investor sentiment, although some of the quarter’s benefit came from ERP implementation timing. Solventum outlines HIS separation and raises 2026 EPS guide
Positive Sentiment: Analyst conviction strengthened. Piper Sandler raised its target to $105 and maintained an overweight rating; Wedbush lifted its target to $101 with an outperform rating; and Stifel increased its target to $100 with a buy rating. UBS also reiterated its buy recommendation. UBS Remains a Buy on Solventum Corporation
Positive Sentiment: Software separation could sharpen the company’s focus. Solventum plans to separate its health information systems business, potentially creating a more focused medical-technology company and unlocking value from the remaining operations. Solventum to hive off healthcare software business

Solventum Company Profile

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.